COMMUNIQUÉS West-GlobeNewswire

Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery
13/01/2026
KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced a strategic collaboration with [...]
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
13/01/2026
Debt-Free Balance Sheet With $21.6 Million in Cash BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology [...]
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
13/01/2026
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, [...]
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
13/01/2026
SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing TEL AVIV, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or [...]
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
13/01/2026
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile Updated clinical [...]
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
13/01/2026
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26 [...]
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
13/01/2026
MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a [...]
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
13/01/2026
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK [...]
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
13/01/2026
Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic [...]
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
13/01/2026
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
13/01/2026
PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
13/01/2026
[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic breast cancer study. No treatment limiting toxicities reported. Patient maintained stable disease at [...]
University of California Berkeley and Glass House Collaboration Leads to State-Funded Research on Cannabis Crop Yields
13/01/2026
LONG BEACH, Calif. and TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
13/01/2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European [...]
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
13/01/2026
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying [...]
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
13/01/2026
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate [...]
Fedora Pharmaceuticals has Re-emerged to Unveil Novel Class of Antibiotics at 2026 Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
13/01/2026
Edmonton, Alberta, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, announced plans to unveil the company’s lead candidate at [...]
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
13/01/2026
As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms [...]
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
13/01/2026
Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide [...]

Pages